Get started
NOD looking for a buying opportunity.A little while ago I expected NOD to make a correction already, but it kept steaming on upwards! Target for this one according to fundamentals is around NOK 130,- However, the big problem with these runs is to find a good buying opportunity, especially if the price is at an all time high, so you don't have previous supports/resistances to work with. So all I can go on is the most recent resistance turned support and the fact that NOD left 3 gaps recently. So if it fills those gaps and revisits this support (and finds support), that would present an excellent buying opportunity on a bullish stock.
OSL:NOD
by duco1
Storebrands strong dividends to support 56 NOK price tag?Storebrands operates in banking, asset management and insurance. The insurance segment has filled up its coffers according to the solvency II regulation, meaning there should be plentiful of cash accessible in the future for dividends which should interest investors looking for good cash flow and dividends. The trade is not a super exciting trade but feels like a rather certain one at current prices which is low by historic standards. The main risk with the trade is negative interest rates which could affect the insurance operations negatively. The main opportunity is a change in investor sentiment towards companies with strong cash flow and dividends. I set my first price target at 56 Norwegian crowns (NOK) which is around recent highs. My stop loss is set beneath the trend line (see the chart) and beneath recent support at 48 NOK. Long term I believe that the Storebrand will trade higher, perhaps reach 60 NOK in 2020. However, the path there is not very likely without retracement. I will use retracements as buying opportunities provided that the overall trade fundamentals remain intact throughout 2020.
OSL:STBLong
by UnknownUnicorn3806802
Suppressed salmon prices to force MOWI ASA to 165 NOK?MOWI ASA (MOWI) is the world's largest producer of Atlantic salmon with operations in Canada, Chile and Europe. Being a salmon producer, the company is highly sensitive to the price of salmon. The price of salmon has been decreasing in 2020 and now trades at circa 5.15 euros per kilogram of salmon. The suppressed salmon price should affect revenues negatively which, short term, could press the stock price down further. Trend, stop loss and price target I believe a trend has formed from the June high 2020 to present date. If this belief is accurate, the trend line should act as a good place for a stop loss at 179.50 Norwegian crowns (NOK). In the same spirit, I set my price target at the July lows of 165.15 NOK. Risks Increase in salmon price (for example due to speculation) while MOWIs sales remains high. Decreased global salmon production while MOWIs production remains high. Increased demand of salmon, for example due to markets opening up for MOWI. Opportunities Decrease in salmon price. Decreased production, for example due to disruption in production. Trade restrictions, for example due to virus outbreak.
OSL:MOWIShort
by UnknownUnicorn3806802
Kitron $KIT.OL breaking up from multiyear uptrend after great Q2Kitron: Q2 2020 – Record performance 10.7.2020 12:46:05 CEST | GlobeNewswire (Excerpt) " (2020-07-10) Kitron today reported strong growth and record profit for the second quarter driven by Defense/Aerospace, Medical devices and Industry sectors. Kitron's revenue for the second quarter was NOK 1 041 million, an increase of 21 per cent compared to last year. Growth adjusted for currency effects was 11 per cent. Profitability expressed as EBIT margin was 8.5 per cent in the second quarter, compared to 6.6 per cent in the same quarter last year. The order backlog ended at NOK 2 102 million, an increase of 45 per cent compared to last year. "
OSL:KITLong
by savepiginvest
ArcticZymes is the Covid-19 stock that is valued at 197 mUSDArcticZymes has entered into an agreement with ReiThera to supply its SAN product for ReiThera’s COVID-19 vaccine candidate Tromsø, 02 July, 2020: ArcticZymes AS (OSE:AZT), a subsidiary of ArcticZymes Technologies ASA, announces that it has entered into a supply agreement with vaccine specialist ReiThera Srl (Rome, Italy) for the supply of Salt Active Nuclease (SAN-HQ) to be used in the development and manufacturing of ReiThera’s novel vaccine candidate against COVID-19. The vaccine candidate, which is based on ReiThera’s viral vector technology, is scheduled to enter clinical trials soon. SAN-HQ has established itself within the viral vector-based biopharmaceutical segment, where viruses are used to deliver genetic material into cells to treat or prevent disease. Due to safety concerns, regulators require manufacturers to minimize and control the amount of exogenous nucleic acids impurities (DNA or RNA not encapsulated by the vector) in the final dosage. Therefore, one or more nuclease treatments are often implemented in the downstream processing of the virus, in which the nuclease digests exogenous DNA. Exogenous DNA can also cause the viral particles to aggregate, which reduces both yield and potency of the vector. One of the key strategies to reduce aggregation involves keeping the virus at elevated salt concentrations. Unlike other commercially available nucleases, SAN-HQ digests nucleic acids with high efficiency at high salt concentrations. Furthermore SAN-HQ is utilized at much lower quantities which means less enzyme needs to be removed from the virus following its use which is another key advantage. To put it into context, the manufacturing process of viral vaccines is a complicated and lengthy multi-stage process with many steps. SAN-HQ is utilised for one part of this process and does not end up as part of the final therapeutic vaccine. Hence, the supply deal relates to the provision of this essential component to streamline part of the process. ReiThera, together with Leukocare AG (Germany) and Univercells S.A. (Belgium), has formed a pan-European consortium to fast-track the development of its vaccine against the novel coronavirus SARS-CoV-2, which causes COVID-19. ArcticZymes AS, CEO, Jethro Holter said: “We are delighted to expand our relationship in supporting ReiThera and its consortium partners with fast tracking its activities to develop a vaccine against the novel coronavirus SARS-CoV-2. ReiThera is a leading European company in genetic vaccine development focused on bringing innovative therapeutics to market via leveraging the best technologies such as ArcticZymes’ SAN-HQ. We look forward to supporting ReiThera in the development and future commercialisation of their vaccine.” “This agreement seamlessly fits with our efforts to scale up SAN-HQ which is supported by the Innovation Norway funding recently granted to ArcticZymes in May 2020. The timely scaling of SAN-HQ production will satisfy future commercial demand from our partners such as ReiThera.” ReiThera’s Project Manager, Marco Soriani, said: “ReiThera’s effort to develop a vaccine against the coronavirus that causes COVID-19 relies on its solid partnerships with key pharmaceutical stakeholders, such as ArcticZymes, which provide crucial technologies to ensure a consistently high-quality product. We look forward to working with ArcticZymes on this important product development program, which aims to tackle the global COVID-19 pandemic.” -ENDS- About ReiThera Srl ReiThera Srl is a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies. The company’s management and scientific teams have developed a highly innovative technological platform based on simian adeno-vectored vaccines against several infectious diseases, such as RSV and Ebola. ReiThera is led by an experienced management team that has worked together for many years in previous successful enterprises, including Okairos (acquired by GSK), and has a long-standing expertise in scalable processes for viral vector manufacturing, supported by a cGMP facility inclusive of filling suite and quality control laboratories. ReiThera is also part of a pan-European consortium focused on the development and large-scale manufacture of an adeno-viral vector vaccine against COVID-19. ReiThera has its headquarters, R&D laboratories and GMP facilities in Rome, Italy.
OSL:AZTLong
by savepiginvest
Risky buyLet's see if it can break the purple line and find support on it, 60% gains possible then (Fat red resistance line). If it breaks the fat red line, who knows how high we can go. If it bounces of the purple and find support on the blue one's 160-280 % gains. Just see where it finds support before buying. I bought already on 0.28 NOK (bullish rsi on daily chart) watched it go down but decided to keep it. I wouldn't throw too much money at it, but i also don't think it will go bankrupt.
OSL:KOA
by pol13337
1
TRVX buy entryAs you know from my last analysis, TRVX gave a buy signal on the weekly chart last friday. Now looking more closely for a good entry. There is a smal gap down to 7.27, which I can easily see filled with a retest of the recently broken black trendline. 2 things will be providing support now, the horizontal support around NOK 6.75-7.20 and the blue upward trendline. I want to see the price hold and bounce from there and then it's a buy for me. So to summarise: - fill gap at 7.27 - finding support at the horizontal support area 6.75-7.20 - Not breaking the upward trendline.
CLong
by duco1